Kentucky Trust Co Takes Position in Johnson & Johnson (NYSE:JNJ)

Kentucky Trust Co acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 22,205 shares of the company's stock, valued at approximately $3,211,000. Johnson & Johnson makes up 1.9% of Kentucky Trust Co's portfolio, making the stock its 12th largest position.

A number of other hedge funds have also recently bought and sold shares of the company. AMF Tjanstepension AB raised its stake in shares of Johnson & Johnson by 14.2% during the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company's stock worth $68,985,000 after purchasing an additional 52,997 shares during the period. Alpha Financial Partners LLC bought a new stake in Johnson & Johnson in the third quarter worth about $209,000. Wealth Group Ltd. purchased a new position in Johnson & Johnson in the third quarter valued at about $213,000. Creative Planning increased its stake in shares of Johnson & Johnson by 4.3% during the 3rd quarter. Creative Planning now owns 988,403 shares of the company's stock worth $160,181,000 after purchasing an additional 41,082 shares during the last quarter. Finally, Swedbank AB raised its holdings in shares of Johnson & Johnson by 5.3% in the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company's stock worth $358,980,000 after purchasing an additional 111,570 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

JNJ has been the subject of several research reports. Barclays increased their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a report on Tuesday, January 28th. Citigroup decreased their price objective on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a report on Wednesday, December 11th. Wolfe Research began coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They set an "outperform" rating and a $190.00 price objective on the stock. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. Finally, Morgan Stanley dropped their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average price target of $170.67.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the business's stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Johnson & Johnson Price Performance

NYSE JNJ traded up $2.94 during trading on Wednesday, reaching $157.93. The company's stock had a trading volume of 6,048,187 shares, compared to its average volume of 8,928,104. The firm has a fifty day moving average of $148.12 and a 200 day moving average of $155.85. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The stock has a market capitalization of $380.23 billion, a PE ratio of 23.75, a P/E/G ratio of 2.50 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same period last year, the firm posted $2.29 earnings per share. Johnson & Johnson's quarterly revenue was up 5.3% on a year-over-year basis. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.14%. Johnson & Johnson's dividend payout ratio (DPR) is presently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.